Acute Myeloid Leukemia Clinical Trials in Pittsburgh, Pennsylvania

12 studies are recruiting for acute myeloid leukemia in Pittsburgh, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

   This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid leukemia (AML). Cytarabine is a drug that inhibits some of …

   Stage

   Phase 2

   Ages

   18 to 59

   Site

   UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

   Locations

   186 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05554393 on ClinicalTrials.gov

2. Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

   This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabi…

   Stage

   Phase 2

   Ages

   18 to 59

   Site

   UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

   Locations

   226 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05554406 on ClinicalTrials.gov

3. MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

   This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrom…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

   Locations

   349 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05564390 on ClinicalTrials.gov

4. Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

   This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed in…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

   Locations

   227 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06317649 on ClinicalTrials.gov

5. Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

   This phase II MyeloMATCH treatment trial studies how well ASTX727 and venetoclax plus enasidenib works compared to ASTX727 and venetoclax alone for the treatment of older patients with newly diagnosed acute myeloid leukemia (AML) or younger patients who are considered unfit for standard treatment, …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

   Locations

   136 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06672146 on ClinicalTrials.gov

6. A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

   This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and …

   Stage

   Phase 3

   Ages

   0 to 21

   Site

   Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania

   Locations

   206 in total

   Run by

   Children's Oncology Group

   See if you can join NCT04293562 on ClinicalTrials.gov

7. A Study of BGB-11417 in Participants With Myeloid Malignancies

   The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh, Pennsylvania

   Locations

   47 in total

   Run by

   BeOne Medicines

   See if you can join NCT04771130 on ClinicalTrials.gov

8. Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

   This phase III trial compares the effect of xylitol dental wipes to dental wipes without xylitol for the reduction of bloodstream infection in children with acute myeloid leukemia (AML). Xylitol is a naturally occurring sugar compound found in fruits and vegetables. Xylitol has been shown to limit …

   Stage

   Phase 3

   Ages

   1 to 25

   Site

   Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania

   Locations

   39 in total

   Run by

   Children's Oncology Group

   See if you can join NCT07022678 on ClinicalTrials.gov

9. Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

   The current standard of care treatment for adult patients with acute myeloid leukemia (AML) consists of chemotherapy and, if indicated, donor stem cell transplantation. Bleximenib blocks the interaction between a protein called menin and another protein called KMT2A in the leukemia cells. When this…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   US-Pittsburgh PA-PITT, Pittsburgh, Pennsylvania

   Locations

   82 in total

   Run by

   Stichting Hemato-Oncologie voor Volwassenen Nederland

   See if you can join NCT07223814 on ClinicalTrials.gov

10. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide informat…

    Stage

    Phase 1

    Ages

    Up to 22

    Site

    Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania

    Locations

    184 in total

    Run by

    PedAL BCU, LLC

    See if you can join NCT04726241 on ClinicalTrials.gov

11. Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation

    This phase 2 study aims to confirm the efficacy observed in the prior phase 1 trial in Cohort 1 and to evaluate the safety of IFN-γ in combination with DLI in Cohort 2, the haploidentical donor alloSCT recipient cohort. The study will further contribute to this effort through the collection of leuk…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

    Locations

    3 in total

    Run by

    Sawa Ito, MD

    See if you can join NCT06529731 on ClinicalTrials.gov

12. Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

    This phase II trial investigates two strategies and how well they work for the reduction of graft versus host disease in patients with acute leukemia or MDS in remission. Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cel…

    Stage

    Phase 2

    Ages

    1 to 60

    Site

    University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

    Locations

    3 in total

    Run by

    Fred Hutchinson Cancer Center

    See if you can join NCT03970096 on ClinicalTrials.gov